Demographic, clinical and laboratory characteristics of patients with SLE
| Characteristic | Value |
| No. of patients | 10 |
| Age at diagnosis, mean±SD years | 39.9±12.5 |
| Age at sample collection, mean±SD years | 57.9±8.8 |
| Female, % | 90 |
| Race/ethnicity, % | |
| Caucasian | 50 |
| African-American | 40 |
| Asian | 10 |
| Disease duration*, mean±SD years | 18.1±11.6 |
| ACR or SLICC classification criteria, % | |
| Malar rash | 40 |
| Discoid rash | 10 |
| Photosensitivity | 50 |
| Oral/nasopharyngeal ulcers | 90 |
| Arthritis | 80 |
| Proteinuria | 30 |
| Pleurisy | 50 |
| Pericarditis | 30 |
| Psychosis | 0 |
| Seizures | 10 |
| ANA | 90 |
| Anti-dsDNA | 70 |
| Anti-Sm | 10 |
| Lupus anticoagulant (by dRVVT) | 40 |
| Leucopenia | 40 |
| Thrombocytopenia | 20 |
| Haemolytic anaemia | 10 |
| Coombs test | 10 |
| At time of sample collection | |
| SLEDAI, mean±SD | 2.5±2.2 |
| PGA, mean±SD | 1.0±0.9 |
| Antihypertensive use, % | 80 |
| Statin use, % | 80 |
| Prednisone use, % | 30 |
| Immunosuppressant use, % | 30 |
| Plaquenil use, % | 70 |
*Up to their date of sample collection.
ACR, American College of Rheumatology; ANA, antinuclear antibody; dRVVT, Dilute Russell's viper venom time; dsDNA, double stranded DNA; PGA, Physician Global Assessment; SD, standard deviation; SLEDAI, SLE Disease Activity Index; SLICC, Systemic Lupus Erythematosus International Collaborating Clinics.